Effect Of Angiotensin-Converting Enzyme Inhibitors And Angiotensin Receptor Blockers On the Clinical Outcome In COVID-19 Patients With Hypertension

AuthorZahra Fakhraeen
AuthorSaeid Bitarafen
AuthorRoohangize Nashibien
AuthorFatemeh Ahmadien
AuthorSafoura Khosravien
AuthorShokrollah Salmanzadehen
OrcidShokrollah Salmanzadeh [0000-0002-5632-9425]en
Issued Date2021-12-31en
AbstractBackground: Hypertension is the main factor to predict the severity and mortality of COVID-19. The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is challenging. This study aimed to investigate the effect of ACEIs and ARBs on clinical outcomes in COVID-19 patients with hypertension. Materials and Methods: This cross-sectional study was carried out on 498 patients who were referred to Razi hospital following COVID-19 development and also had hypertension. Patients were divided into two groups receiving drugs in the ACEIs and ARB's groups and those not receiving these drugs. The primary outcome was death up to one month after the onset of symptoms. Results: Cardiovascular disease in patients taking ACEIs/ARBs was higher (p0.05). Seventy-nine patients (15.86%) were admitted to ICU in which 62.03% of these patients died while the non-ICU mortality rate was 14.8% (Odds Ratio = 9.40; 95% CI: 5.54 to 15.95, pen
DOIhttps://doi.org/10.22037/jcma.v6i4.35596en
URIhttps://brieflands.com/journals/jcma/articles/149739en
KeywordCOVID-19en
KeywordSARS-CoV2en
Keywordangiotensin-converting enzyme inhibitorsen
Keywordangiotensin receptor blockersen
KeywordARBsen
KeywordACEien
PublisherBrieflandsen
TitleEffect Of Angiotensin-Converting Enzyme Inhibitors And Angiotensin Receptor Blockers On the Clinical Outcome In COVID-19 Patients With Hypertensionen
TypeOriginal Articlesen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
165869.pdf
Size:
545.41 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF